PL371799A1 - Krystaliczny produkt mikronizacji bromku tiotropium - Google Patents

Krystaliczny produkt mikronizacji bromku tiotropium

Info

Publication number
PL371799A1
PL371799A1 PL03371799A PL37179903A PL371799A1 PL 371799 A1 PL371799 A1 PL 371799A1 PL 03371799 A PL03371799 A PL 03371799A PL 37179903 A PL37179903 A PL 37179903A PL 371799 A1 PL371799 A1 PL 371799A1
Authority
PL
Poland
Prior art keywords
tiotropium bromide
crystalline tiotropium
micronized crystalline
sup
drug
Prior art date
Application number
PL03371799A
Other languages
English (en)
Other versions
PL220730B1 (pl
Inventor
Helmut Bender
Hagen Graebner
Konrad Schindler
Michael Josef Friedrich Trunk
Michael Walz
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co.Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27797948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL371799(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma Gmbh & Co.Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co.Kg
Publication of PL371799A1 publication Critical patent/PL371799A1/pl
Publication of PL220730B1 publication Critical patent/PL220730B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Glass Compositions (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hybrid Cells (AREA)

Abstract

Wynalazek dotyczy krystalicznego produktu mikronizacji bromku (1α,2β,4β,5α,7β)-7-[ (hydroksydi-2-tienyloacetylo)oksy]-9,9-dimetylo-3-oksa-9-azoniatricyklo[3.3.1.0 <sup>2,4</sup>]nonanu, sposobu jego wytwarzania, jak również jego zastosowania w procesie wytwarzania leku, w szczególności w procesie wytwarzania leku o właściwościach antycholinergicznych.
PL371799A 2002-03-20 2003-03-10 Sposób wytwarzania produkt mikronizacji krystalicznego bromku tiotropium, jego zastosowanie, lek i proszek do inhalacji, sposób wytwarzania proszku, oraz kapsułka PL220730B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10212264A DE10212264A1 (de) 2002-03-20 2002-03-20 Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels

Publications (2)

Publication Number Publication Date
PL371799A1 true PL371799A1 (pl) 2005-06-27
PL220730B1 PL220730B1 (pl) 2015-12-31

Family

ID=27797948

Family Applications (1)

Application Number Title Priority Date Filing Date
PL371799A PL220730B1 (pl) 2002-03-20 2003-03-10 Sposób wytwarzania produkt mikronizacji krystalicznego bromku tiotropium, jego zastosowanie, lek i proszek do inhalacji, sposób wytwarzania proszku, oraz kapsułka

Country Status (36)

Country Link
EP (3) EP3053921A1 (pl)
JP (1) JP4331619B2 (pl)
KR (2) KR101021430B1 (pl)
CN (2) CN101220025A (pl)
AR (1) AR039017A1 (pl)
AT (1) ATE369365T1 (pl)
AU (1) AU2003212327B2 (pl)
BR (1) BRPI0308513B8 (pl)
CA (1) CA2479652C (pl)
CO (1) CO5611105A2 (pl)
CY (2) CY1106923T1 (pl)
DE (2) DE10212264A1 (pl)
DK (2) DK1785422T3 (pl)
EA (1) EA007064B1 (pl)
EC (1) ECSP045310A (pl)
ES (2) ES2291619T5 (pl)
HR (1) HRP20040855B1 (pl)
HU (1) HUE031876T2 (pl)
IL (2) IL163841A0 (pl)
LT (1) LT1785422T (pl)
ME (1) ME02764B (pl)
MX (1) MXPA04009056A (pl)
MY (1) MY139720A (pl)
NO (2) NO346754B1 (pl)
NZ (1) NZ535808A (pl)
PE (1) PE20030838A1 (pl)
PL (1) PL220730B1 (pl)
PT (2) PT1785422T (pl)
RS (1) RS57551B1 (pl)
SA (1) SA03240098B1 (pl)
SI (1) SI1487832T2 (pl)
TW (1) TWI345975B (pl)
UA (1) UA78295C2 (pl)
UY (1) UY27725A1 (pl)
WO (1) WO2003078429A1 (pl)
ZA (1) ZA200405636B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
EP2083007B1 (de) 2003-11-03 2013-04-24 Boehringer Ingelheim International Gmbh Tiotropiumsalze, Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittelformulierungen
KR20060117334A (ko) 2003-11-03 2006-11-16 베링거 인겔하임 인터내셔날 게엠베하 티오트로피움 염의 제조방법, 티오트로피움 염 및 이를함유하는 약제학적 조성물
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
DE102004024451A1 (de) 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
DK1881980T3 (da) 2005-05-02 2012-10-01 Boehringer Ingelheim Int Nye krystalline former af tiotropiumbromid
MX2007013691A (es) * 2005-05-02 2008-01-21 Boehringer Ingelheim Int Nuevas formas cristalinas de bromuro de tiotropio.
CA2619402C (en) 2005-08-15 2015-02-03 Boehringer Ingelheim International Gmbh Method for producing betamimetics
US20070086957A1 (en) * 2005-10-10 2007-04-19 Thierry Bouyssou Combination of medicaments for the treatment of respiratory diseases
DE102005059602A1 (de) * 2005-12-14 2007-06-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mikronisierung
US9108962B2 (en) 2005-12-19 2015-08-18 Sicor, Inc. Forms of tiotropium bromide and processes for preparation thereof
RS52663B2 (sr) 2005-12-19 2018-05-31 Sicor Inc Nova kristalna forma tiotropijum bromida i proces njene pripreme
CN100999521B (zh) * 2006-01-13 2010-12-08 江苏正大天晴药业股份有限公司 结晶性抗胆碱药噻托溴铵
GB0716026D0 (en) 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
WO2011093815A2 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Pharmaceutical compositions comprising formoterol and mometasone
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
PT106142B (pt) * 2012-02-10 2014-07-18 Hovione Farmaci Ncia S A Processo para a preparação de brometo de tiotrópio
US20150150802A1 (en) 2012-07-05 2015-06-04 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhaler compositions comprising long acting muscarinic antagonists
EP2705838A1 (en) * 2012-09-06 2014-03-12 Xspray Microparticles Ab Tiotropium preparations
EP2897955B1 (en) * 2012-09-11 2019-11-06 Bilgic, Mahmut New tiotropium bromide crystalline form
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
NZ728435A (en) 2014-09-09 2017-11-24 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
EP3159278A1 (en) * 2015-10-23 2017-04-26 Arven Ilac Sanayi Ve Ticaret A.S. Blister for tiotropium bromide inhalable formulation
DK3159277T3 (da) * 2015-10-23 2019-09-02 Arven Ilac Sanayi Ve Ticaret As Blister til inhalerbar formulering af tiotropiumbromid
CN115737610B (zh) * 2021-12-13 2024-02-27 苏州欧米尼医药有限公司 一种噻托溴铵吸入粉雾剂及其活性成分的气流粉碎方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
US4811731A (en) 1985-07-30 1989-03-14 Glaxo Group Limited Devices for administering medicaments to patients
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
DE4318455A1 (de) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Kapselhalterung
DE19515625C2 (de) * 1995-04-28 1998-02-19 Boehringer Ingelheim Kg Verfahren zur Herstellung von enantiomerenreinen Tropasäureestern
FR2779347A1 (fr) * 1998-06-05 1999-12-03 Arlette Guerry Procede de micronisation de substances medicamenteuses
CA2338680C (en) 1998-08-04 2008-10-14 Jago Research Ag Medicinal aerosol formulations
EP1131059B1 (de) * 1998-11-13 2003-03-05 Jago Research Ag Trockenpulver zur inhalation
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
CA2371046A1 (en) † 1999-04-23 2000-11-02 Eugene Lukanidin Therapeutic compositions and methods for enhancing angiogenesis
WO2001026630A1 (en) 1999-10-12 2001-04-19 Kaken Pharmaceutical Co., Ltd. Powdery inhalational preparations and process for producing the same
SK285389B6 (sk) 2000-10-12 2006-12-07 Boehringer Ingelheim Pharma Kg Inhalačný prášok s obsahom tiotrópia, kapsula s jeho obsahom a ich použitie
CN100519558C (zh) 2000-10-12 2009-07-29 贝林格尔英格海姆法玛两合公司 结晶单水合物、其制备方法及其在制备药物组合中的用途
DE10126924A1 (de) 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalationskapseln
DE50207943D1 (de) 2001-06-22 2006-10-05 Boehringer Ingelheim Pharma Kristallines anticholinergikum, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
US7309707B2 (en) 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
US7244842B2 (en) 2002-11-15 2007-07-17 Orchid Chemicals & Pharmaceuticals Ltd. Amorphous hydrate of a cephalosporin antibiotic
DE102005059602A1 (de) 2005-12-14 2007-06-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mikronisierung
CN102127069A (zh) 2010-01-20 2011-07-20 鲁南制药集团股份有限公司 噻托溴铵晶体

Also Published As

Publication number Publication date
KR101094091B1 (ko) 2011-12-15
ME02764B (me) 2011-05-10
CN100368410C (zh) 2008-02-13
EA200401142A1 (ru) 2005-04-28
CA2479652A1 (en) 2003-09-25
DK1785422T3 (en) 2017-02-27
NO20190824A1 (no) 2004-10-14
ES2615460T3 (es) 2017-06-07
KR101021430B1 (ko) 2011-03-15
IL163841A0 (en) 2005-12-18
EP1487832B2 (de) 2018-08-29
WO2003078429A1 (de) 2003-09-25
HK1078871A1 (zh) 2006-03-24
HRP20040855A2 (en) 2005-06-30
EP3053921A1 (de) 2016-08-10
MXPA04009056A (es) 2005-01-25
CN101220025A (zh) 2008-07-16
PE20030838A1 (es) 2003-11-21
KR20050008662A (ko) 2005-01-21
IL163841A (en) 2015-10-29
EP1785422A8 (de) 2010-06-23
ECSP045310A (es) 2004-10-26
UY27725A1 (es) 2003-10-31
CN1642952A (zh) 2005-07-20
EP1785422A1 (de) 2007-05-16
NO346754B1 (no) 2022-12-12
EP1487832A1 (de) 2004-12-22
SI1487832T1 (sl) 2007-12-31
PT1487832E (pt) 2007-08-27
CY1106923T1 (el) 2012-09-26
ES2291619T3 (es) 2008-03-01
CO5611105A2 (es) 2006-02-28
BR0308513A (pt) 2005-01-04
AU2003212327B2 (en) 2009-02-05
NO344427B1 (no) 2019-12-02
DE50307883D1 (de) 2007-09-20
UA78295C2 (en) 2007-03-15
CA2479652C (en) 2012-07-10
DK1487832T3 (da) 2007-11-05
ZA200405636B (en) 2006-01-25
JP2005526776A (ja) 2005-09-08
HUE031876T2 (en) 2017-08-28
LT1785422T (lt) 2017-02-10
KR20100135983A (ko) 2010-12-27
DK1487832T4 (en) 2018-12-10
JP4331619B2 (ja) 2009-09-16
ATE369365T1 (de) 2007-08-15
AU2003212327A1 (en) 2003-09-29
AR039017A1 (es) 2005-02-02
SI1487832T2 (sl) 2018-11-30
EP1487832B1 (de) 2007-08-08
MY139720A (en) 2009-10-30
EP1487832B9 (de) 2019-01-23
NO20044003L (no) 2004-10-14
CY1118855T1 (el) 2018-01-10
ES2291619T5 (es) 2018-12-07
PT1785422T (pt) 2017-02-17
PL220730B1 (pl) 2015-12-31
TWI345975B (en) 2011-08-01
EA007064B1 (ru) 2006-06-30
DE10212264A1 (de) 2003-10-02
RS57551B1 (sr) 2018-10-31
HRP20040855B1 (en) 2012-11-30
TW200305421A (en) 2003-11-01
MEP46708A (en) 2011-02-10
BRPI0308513B1 (pt) 2016-04-19
SA03240098B1 (ar) 2008-03-24
EP1785422B1 (de) 2016-11-16
NZ535808A (en) 2005-09-30
BRPI0308513B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
PL371799A1 (pl) Krystaliczny produkt mikronizacji bromku tiotropium
MEP62008A (en) Crystalline anticholinergic, method for its production, and use thereof in the production of a drug
MEP40008A (en) Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament
MEP40608A (en) Method for producing the anticholinergic agent tiotropium bromide
WO2002072095A3 (de) Tiotropiumsalzen zur behandlung von inflammatorischen erkrankungen
EA006966B1 (ru) Эфиры флуоренкарбоновых кислот, способ их получения, а также их применение в качестве лекарственных средств
MA27475A1 (fr) Composes de pyrazolo [3,4-b] pyridine et leur utilisation en tant qu&#39;inhibiteurs de phosphodiesterase
US6790856B2 (en) Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments
EP1695701A3 (de) HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
MXPA05005443A (es) Esteres de acido carbamico con actividad anticolinergica.
WO2003082244A3 (de) Hfa-suspensionsformulierungen eines anhydrats
EP1497288A1 (de) Neue ester hydroxy-substituierter stickstoffheterocyclen als antagonisten des muskarinischen m3 rezeptors, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
HU0400891D0 (en) 7 h-pyrrolo[2,3-d]pyrimidine derivatives and their pharmaceutically acceptable salts, pharmaceutical compositions containing them and process for the production of the compounds
AU2003206759A1 (en) Xanthene-carboxylic acid esters of tropenol and scopine as m3 antagonists, method for producing the same and use thereof as medicaments
ZA200404366B (en) Novel fluorene carboxylic acid esters methods for the production thereof and use of the same as pharmaceuticals